Glutamatergic mechanisms in schizophrenia

Annual Review of Pharmacology and Toxicology

Volumn 42, Issue , 2002, Pages 165-179

  Tsai, Guochuan ^a   Coyle, Joseph T ^a  

^a Mailman Research Center   (United States)

Author keywords

D serine; Glutamate; Glycine; N methyl D aspartate (NMDA); Psychosis

Indexed keywords

CLOZAPINE; CYCLOSERINE; DEXTRO SERINE; DIZOCILPINE; DOPAMINE 2 RECEPTOR; GLUTAMIC ACID; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE;

AMINO ACID BRAIN LEVEL; BINDING COMPETITION; BINDING SITE; BRAIN DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DOPAMINE RELEASE; DRUG EFFICACY; DRUG RECEPTOR BINDING; HUMAN; LIMBIC CORTEX; NEGATIVE SYNDROME; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; ONSET AGE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ANIMALS; DOPAMINE; GLUTAMIC ACID; HUMANS; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 0036174640     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.42.082701.160735     Document Type: Review

References (101)

1. Catching up on schizophrenia: Natural history and neurobiology
2. Search for schizophrenia vulnerability genes
3. Thalamic abnormalities in schizophrenia visualized through magnetic resonance imaging averaging
4. Schizophrenia-a brain disease? A critical review of structural and functional cerebral abnormality in the disorder
5. Brain imaging in schizophrenia
6. MRI anatomy of schizophrenia
7. Progressive cortical change during adolescence in childhood-onset schizophrenia: A longitudinal magnetic resonance imaging study
8. Cognitive dysfunction in schizophrenia
9. N-acetylaspartate in neuropsychiatric disorder
10. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis
11. Specific relationhsip between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia
12. The current status of the dopamine hypothesis of schizophrenia
13. D2 dopamine receptors in neuroleptic-naive schizophrenic patients
14. Increased dopamine transmission in schizophrenia: Relationship to illness phases
15. New insights into the biology of schizophrenia through the mechanism of action of clozapine
16. The glutamatergic dysfunction hypothesis for schizophrenia
17. Diverse role of L-glutamate acid in brain signal tranduction
18. Cloned glutamate receptors
19. Glycine potentiates the NMDA response in cultured mouse brain neurons
20. The glycine site of the NMDA receptor - Five years on
21. Purification of serine racemase: Biosynthesis of the neuromodulator D-serine
22. Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition
23. The glutamate receptor ion channels
24. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs
25. Recent advances in the phencyclidine model of schizophrenia
26. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
27. Dissociation of ketamine effects on rule acquisition and rule implementation: Possible relevance to NMDA receptor contributions to executive cognitive functions
28. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders
29. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia
30. Clozapine blunts N-methyl-D-aspartate antagonistinduced psychosis: A study with ketamine
31. Ketamine activates psychosis and alters limbic blood flow in schizophrenia
32. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers
33. The neuropsychopharmacology of phencyclidine: From NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia
34. NMDAdependent modulation of CA1 local circuit inhibition
35. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
36. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
37. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
38. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia
39. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
40. The nagging question of the function of N-acetylaspartylglutamate
41. Increased cortical kynureninatecontent in schizophrenia
42. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers
43. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia
44. Asymmetrical loss of glutamate receptors subtype in left hippocampus in schizophrenia
45. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem
46. Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia
47. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia
48. NMDA-associated glycine binding site increases in schizophrenic brains
49. Increases in strychnine-insensitive glycine binding sites in cerebral cortex of chronic schizophrenia: Evidence for glutamate hypothesis
50. Decreased expression of mRNAs encoding non-NMDA glutamate receptor GluR1 and GluR2 in medical temporal lobe neurons in schizophrenia
51. Editing for an AMPA receptor subunit RNA in prefrontal cortex and striatum in Alzheimer's disease, Huntington's disease and schizophrenia
52. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia
53. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia
54. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
55. Ionotropic glutamate receptors and expression of Nmethyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
56. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia
57. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
58. Reversal of phencyclidine effects by group II metabotropic glutamate recpetor agonist in rats
59. Glycyldodecylamide, a phencyclidine behavioral antagonist, blocks cortical glycine uptake: Implications for schizophrenia and substance abuse
60. Prefrontal cortex regulates burst firing and transmitter release in rat mesolimbic dopamine neurons studied in vivo
61. Blockade of the locomotor stimulant effects of cocaine and methamphetamine by glutamate antagonists
62. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
63. Glutamate modulation of dopamine measured in vivo with positron emission tomography (PET) and 11C-raclopride in normal human subjects
64. Effects of (S)ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans
65. Differential regulation, by MK-801, of dopamine receptor gene expression in rat nigrostriatal and mesocorticolimbic systems
66. Dopamine in schizophrenia: A review and reconceptualization
67. Stress preferentially increased extraneuronal levels of excitatory amino acids in prefrontal cortex: Comparison to hippocampus and basal ganglia
68. Glutamatergic control of dopamine release during stress in the rat prefrontal cortex
69. Interaction between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease
70. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
71. Excitotoxic amino acids and neuropsychiatric disorders
72. Amelioration of negative symptoms in schizophrenia by glycine
73. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia
74. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: An open-label trial
75. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia
76. D-serine added to antipsychotic for the treatment of schizophrenia
77. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection
78. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes
79. D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics
80. A dose-finding trial of Dcycloserine added to neuroleptics for negative symptoms in schizophrenia
81. Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients
82. D-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study
83. D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia
84. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: A double-blind, parallel, placebo-controlled study
85. Doubleblind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia
86. A placebocontrolled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
87. D-serine added to clozapine for the treatment of schizophrenia
88. D-cycloserine added to clozapine for patients with schizophrenia
89. Synergistic interactions between ampakines and antipsychotic drugs
90. Effects of an AMPA receptor modulator on methamphetamine-induced hyperactivity in rats
91. A preliminary dose escalation trial of CX516 (Ampakine) added to clozapine in schizophrenia
92. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drug
93. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain
94. NMDA antagonist neurotoxicity: Mechanisms and prevention
95. Phencyclidine poisoning in young children
96. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity
97. Glutamate receptor dysfunction and schizophrenia
98. The effects of early and sustained intervention on the long-term morbidity of schizophrenia
99. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein
100. Synapse structure: Glutamate receptors connected by the shanks